Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | DAO | P14920 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661774 | 1.00 | MAOB (0.52) | MAOBAPPMAOADAOTP53 | |
| SCHEMBL31647232 | 0.83 | APP (0.55) | MAOBAPPMAOADAOSMN1; SMN2 | |
| SCHEMBL28804423 | 0.83 | MAPK1 (0.54) | MAOBMAOADAOTP53SMN1; SMN2 | |
| SCHEMBL191181 | 0.82 | DYRK1A (0.53) | MAOBAPPMAOADAOTP53 | |
| SCHEMBL7815567 | 0.80 | MAOB (0.50) | MAOBAPPMAOADAOTP53 | |
| SCHEMBL9876887 | 0.80 | HSD17B10 (0.50) | MAOBMAOASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL28804281 | 0.78 | HTR1A (0.53) | MAOBAPPMAOADAOTP53 | |
| SCHEMBL8255854 | 0.78 | APP (0.65) | MAOBAPPMAOADAOTP53 | |
| SCHEMBL7956847 | 0.78 | APP (0.56) | MAOBAPPMAOADAOTP53 | |
| SCHEMBL27595525 | 0.77 | MAPT (0.50) | APPTP53SMN1; SMN2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716367-B | Method for preparing 4-mercaptopyridine compound by micro-flow field reactor technology | 南京工业大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-114716367-A | Method for preparing 4-mercaptopyridine compound by virtue of micro-flow field reactor technology | 南京工业大学 | 2022-07-08 | — | — | CN | disclosed |
| EP-1986645-B1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
| CN-101437512-A | Glucokinase activators | ARRAY BIOPHARMA INC (US) | 2009-05-20 | — | — | CN | disclosed |
| EP-1986645-A1 | GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007089512-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | MAOB 2788/4885APP 3692/4885MAOA 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.